BioCryst Pharmaceuticals Inc (NASDAQ: BCRX) has reported a loss for its second fiscal quarter (ending June 30) of $-0.06 versus a loss $-0.40 for the same period a year ago. This result exceeded the consensus estimate of $-0.16 by $0.10. For the latest four quarters through June 30, E.P.S. were $-0.73 versus $-1.29 for the same period a year ago.
Recent Price Action
BioCryst Pharmaceuticals Inc (NASDAQ: BCRX) stock enjoyed a very large increase of 7.0% on 8/5/24. The shares closed at $7.51. Moreover, this advance was accompanied by unusually high trading volume at 198% of normal. The stock has been strong relative to the market over the last nine months but has declined -4.3% during the last week.
Current PriceTarget Research Rating
BCRX is expected to continue to be a major Value Eraser reflecting capital returns that are forecasted to fall short of the cost of capital.
BioCryst Pharmaceuticals is currently unrated.
Rating Review
The stock is currently unrated.
Be the first to comment